Drug Search Results
More Filters [+]

Buclizine

Alternative Names: buclizine, bucladin-s
Latest Update: 2024-12-19
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: Belgium | Brazil | Colombia | Ecuador | India | Ireland | Israel | Italy | Malta | Morocco | Peru | Philippines | Portugal | Saudi Arabia | Singapore | Spain | Taiwan | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Buclizine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events

Date

Type

Title